Highlights
- Market Cap
- $26.89B
- Enterprise Value
- $30.46B
- EPS (TTM)
- $8.82
- PE Ratio
- 20.77
- PEG Ratio
- 1.44
- Total Revenue (TTM)
- $9.81B
- Gross Profit (TTM)
- $6.91B
- EBITDA (TTM)
- $3.10B
- Year Range
- $110.04 - $202.41
- Target Price
- $188.75
- ROA (TTM)
- 4.39%
- ROE (TTM)
- 7.08%
Share Price Chart
Loading graphics...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
Performance Chart
The chart shows the growth of an initial investment of $10,000 in Biogen Inc., comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.
Loading graphics...
Returns By Period
Biogen Inc. (BIIB) has returned 4.17% so far this year and 33.97% over the past 12 months. Over the last ten years, BIIB has returned -3.45% per year, falling short of the S&P 500 Index benchmark, which averaged 12.16% annually.
Biogen Inc.
- 1D
- -2.26%
- 1M
- -4.43%
- YTD
- 4.17%
- 6M
- 30.88%
- 1Y
- 33.97%
- 3Y*
- -12.96%
- 5Y*
- -8.04%
- 10Y*
- -3.45%
Benchmark (S&P 500 Index)
- 1D
- 2.91%
- 1M
- -5.09%
- YTD
- -4.63%
- 6M
- -2.39%
- 1Y
- 16.33%
- 3Y*
- 16.69%
- 5Y*
- 10.18%
- 10Y*
- 12.16%
Monthly Returns
Based on dividend-adjusted daily data since Sep 17, 1991, BIIB's average daily return is +0.11%, while the average monthly return is +2.01%. At this rate, your investment would double in approximately 2.9 years.
Historically, 52% of months were positive and 48% were negative. The best month was Jun 2000 with a return of +83.8%, while the worst month was Feb 2005 at -40.5%. The longest winning streak lasted 13 consecutive months, and the longest losing streak was 10 months.
On a daily basis, BIIB closed higher 48% of trading days. The best single day was Nov 4, 2020 with a return of +44.0%, while the worst single day was Feb 28, 2005 at -42.6%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 2.22% | 6.63% | -4.43% | 4.17% | |||||||||
| 2025 | -5.88% | -2.38% | -2.60% | -11.52% | 7.19% | -3.24% | 1.92% | 3.30% | 5.94% | 10.13% | 18.03% | -3.35% | 15.09% |
| 2024 | -4.68% | -12.03% | -0.63% | -0.38% | 4.71% | 3.06% | -8.03% | -3.96% | -5.33% | -10.24% | -7.68% | -4.80% | -40.91% |
| 2023 | 5.05% | -7.23% | 3.03% | 9.42% | -2.57% | -3.90% | -5.15% | -1.05% | -3.87% | -7.58% | -1.46% | 10.55% | -6.55% |
| 2022 | -5.80% | -6.63% | -0.19% | -1.50% | -3.59% | 1.97% | 5.45% | -9.15% | 36.66% | 6.16% | 7.67% | -9.26% | 15.42% |
| 2021 | 15.42% | -3.44% | 2.52% | -4.44% | 0.06% | 29.46% | -5.64% | 3.73% | -16.50% | -5.76% | -11.60% | 1.77% | -2.02% |
Benchmark Metrics
Biogen Inc. has an annualized alpha of 18.74%, beta of 1.03, and R² of 0.11 versus S&P 500 Index. Calculated based on daily prices since September 18, 1991.
- This stock captured 127.15% of S&P 500 Index gains and 108.02% of its losses — amplifying both gains and losses, but participating more in upside than downside.
- R² of 0.11 means this stock moves largely independently of S&P 500 Index — capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.
- Alpha
- 18.74%
- Beta
- 1.03
- R²
- 0.11
- Upside Capture
- 127.15%
- Downside Capture
- 108.02%
Return for Risk
Risk / Return Rank
BIIB ranks 72 for risk / return — better than 72% of stocks on our site. You're getting solid returns for the risk taken. A good sign, especially for investors who want growth without excessive volatility.
Return / Risk — by metrics
The table below present risk-adjusted performance metrics for Biogen Inc. (BIIB) and compare them to a chosen benchmark (S&P 500 Index).
| BIIB | Benchmark | Difference | |
|---|---|---|---|
Sharpe ratioReturn per unit of total volatility | 0.99 | 0.90 | +0.10 |
Sortino ratioReturn per unit of downside risk | 1.63 | 1.39 | +0.25 |
Omega ratioGain probability vs. loss probability | 1.19 | 1.21 | -0.02 |
Calmar ratioReturn relative to maximum drawdown | 1.90 | 1.40 | +0.50 |
Martin ratioReturn relative to average drawdown | 4.80 | 6.61 | -1.81 |
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month. | |||
Explore BIIB risk-adjusted metrics in detail
Dive deeper into individual metrics with historical trends, benchmark comparisons, and performance across different time periods.
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading graphics...
Worst Drawdowns
The table below displays the maximum drawdowns of the Biogen Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Biogen Inc. was 89.98%, occurring on Dec 16, 1994. Recovery took 258 trading sessions.
The current Biogen Inc. drawdown is 61.48%.
Depth | Start | To Bottom | Bottom | To Recover | End | Total |
|---|---|---|---|---|---|---|
| -89.98% | Oct 17, 1991 | 802 | Dec 16, 1994 | 258 | Dec 26, 1995 | 1060 |
| -76.18% | Mar 23, 2015 | 2530 | Apr 10, 2025 | — | — | — |
| -66.51% | Mar 7, 2000 | 34 | Apr 24, 2000 | 109 | Sep 27, 2000 | 143 |
| -62.59% | Dec 19, 2000 | 555 | Mar 11, 2003 | 1158 | Oct 15, 2007 | 1713 |
| -61.96% | Oct 8, 1997 | 227 | Sep 1, 1998 | 76 | Dec 18, 1998 | 303 |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading graphics...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of Biogen Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how Biogen Inc. is priced in the market compared to other companies in the Drug Manufacturers - General industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PE Ratio
The chart displays the Price-to-Earnings (P/E) ratio for BIIB, comparing it with other companies in the Drug Manufacturers - General industry. Currently, BIIB has a P/E ratio of 20.8. This P/E ratio is in line with the industry average, suggesting the stock may be fairly valued relative to its earnings.
PEG Ratio
The chart shows the Price/Earnings to Growth (PEG) ratio for BIIB compared to other companies in the Drug Manufacturers - General industry. BIIB currently has a PEG ratio of 1.4. This PEG ratio is higher than the industry average, which may suggest the stock is overvalued relative to its expected earnings growth.
PS Ratio
This chart shows the Price-to-Sales (P/S) ratio for BIIB relative to other companies in the Drug Manufacturers - General industry. Currently, BIIB has a P/S ratio of 2.7. This P/S ratio falls within the average range for the industry, suggesting the stock is fairly valued based on its revenue.
PB Ratio
The chart illustrates the Price-to-Book (P/B) ratio for BIIB in comparison with other companies in the Drug Manufacturers - General industry. Currently, BIIB has a P/B value of 1.5. This P/B ratio is in line with the industry average, suggesting the stock is valued fairly in relation to its book value.
Income Statement
| TTM | |
|---|---|
Revenue | — |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | — |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | — |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |